Ongoing ADT Use Up to 36 Months Not Linked With Cognitive Decline
Ongoing use of androgen-deprivation therapy for up to 36 months is not associated with cognitive decline among men with prostate cancer.
Ongoing use of androgen-deprivation therapy (ADT) for up to 36 months is not associated with cognitive decline among men with prostate cancer, according to a study published in Cancer.1
Researchers evaluated 3 groups of men who were at least 50 years of age and were matched for age and education. Seventy-seven patients had non-metastatic prostate cancer and initiated continuous ADT, 82 patients had prostate cancer and were not receiving ADT, and 82 were healthy controls.
Over the study period of 26 months, the researchers administered 14 neuropsychological tests that examined 8 cognitive domains on 5 separate occasions.
Through mixed effects models that were adjusted for age and education, the researchers found that ADT use was not associated with significant changes over time in any cognitive test, when compared with healthy controls.
The percentage of patients who declined by at least 1.5 standard deviations in at least 2 tests, or at least 2 standard deviations in at least 1 test, was similar across the observed groups.
RELATED: Continuing Docetaxel Therapy May Improve Survival in Prostate Cancer
There was no significant worsening of cognitive function among patients treated with ADT, compared to controls, upon a global summary of cognitive change.